Benzinga · Feb 25, 2026
EN
NASDAQ · ENVB
Enveric Biosciences, Inc.
Healthcare · Biotechnology
$1.55
Down-$0.04 (-2.58%)
Updated Aug 14, 2026, 1:10 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.25M
- P/E ratio
- -0.12
- Dividend yield
- 0.00%
- 52-week range
- $1.25 – $17.64
- Volume
- 55.66K
- Avg. volume
- 85.35K
Price performance
ENVB price history
1M range · 20 trading sessions · Daily adjusted prices
ENVB closed at $1.55 after 20 trading sessions, up 13.97% for the selected period.
- Last close
- $1.55
- Period change
- +13.97%
- Period low
- $1.27
- Period high
- $1.69
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $1.52 | $1.62 | $1.52 | $1.55 | 55.66K |
| Aug 11, 2026 | $1.53 | $1.5699 | $1.48 | $1.55 | 34.55K |
| Aug 10, 2026 | $1.56 | $1.5799 | $1.51 | $1.54 | 25.34K |
| Aug 7, 2026 | $1.60 | $1.63 | $1.53 | $1.55 | 49.32K |
| Aug 6, 2026 | $1.71 | $1.71 | $1.43 | $1.56 | 262.71K |
| Aug 5, 2026 | $1.58 | $1.68 | $1.53 | $1.67 | 414.69K |
| Aug 4, 2026 | $1.58 | $1.75 | $1.5629 | $1.69 | 147.61K |
| Aug 3, 2026 | $1.56 | $1.6299 | $1.52 | $1.60 | 85.38K |
| Jul 31, 2026 | $1.47 | $1.58 | $1.4301 | $1.57 | 78.56K |
| Jul 30, 2026 | $1.31 | $1.46 | $1.285 | $1.43 | 68.06K |
| Jul 29, 2026 | $1.28 | $1.40 | $1.2627 | $1.33 | 209.55K |
| Jul 28, 2026 | $1.32 | $1.34 | $1.28 | $1.33 | 110.59K |
| Jul 27, 2026 | $1.32 | $1.345 | $1.25 | $1.34 | 133.64K |
| Jul 24, 2026 | $1.30 | $1.31 | $1.25 | $1.29 | 107.45K |
| Jul 23, 2026 | $1.31 | $1.34 | $1.25 | $1.32 | 118.61K |
| Jul 22, 2026 | $1.30 | $1.44 | $1.30 | $1.34 | 166.41K |
| Jul 21, 2026 | $1.28 | $1.34 | $1.2701 | $1.32 | 85.59K |
| Jul 20, 2026 | $1.32 | $1.33 | $1.27 | $1.27 | 84.75K |
| Jul 17, 2026 | $1.44 | $1.44 | $1.30 | $1.34 | 176.24K |
| Jul 16, 2026 | $1.34 | $1.4932 | $1.335 | $1.36 | 359.62K |
Latest ENVB news
The latest Smart Investors Daily articles mentioning ENVB.
Stock researchCompany · Overview
ENVB research
Overview
Company profile and research snapshot.
Company profile
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 6, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 30, 2024 | HC Wainwright & Co. | Buy | — |
| Jun 1, 2022 | Alliance Global Partners | Buy | — |
| Mar 8, 2022 | Aegis Capital | Hold | — |
| Jul 8, 2021 | Aegis Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 25, 2026
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested
Gilgamesh withdraws patent challenge against Enveric, leaving the key psilocybin patent uncontested.
Benzinga · Feb 25, 2026
Enveric Biosciences Announces Withdrawal Of Petition Against Patent; Co Says There Are 'No Remaining Challenges' Pending Against Patent
Benzinga · Feb 19, 2026
Enveric Biosciences shares are trading higher after the company announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
